Inflammatory Markers in Schizophrenia

Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

Jonathan M. Meyer, Joseph Patrick McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment. Methods: The IM outcomes were compared between antipsychotic treatment groups in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial phase 1 with subjects with laboratory assessments at baseline and 3 months (n = 789). Results: There were significant treatment differences in CRP, E-selectin, and ICAM-1 at 3 months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities as measured by changes in systemic inflammation. C-reactive protein might emerge as a useful target for CV risk outcomes in schizophrenia patients.

Original languageEnglish (US)
Pages (from-to)1013-1022
Number of pages10
JournalBiological Psychiatry
Volume66
Issue number11
DOIs
StatePublished - Dec 1 2009

Fingerprint

olanzapine
Clinical Trials, Phase I
C-Reactive Protein
Antipsychotic Agents
Schizophrenia
Intercellular Adhesion Molecule-1
E-Selectin
Perphenazine
Risperidone
Social Adjustment
Vascular Cell Adhesion Molecule-1
Clinical Trials
Inflammation

Keywords

  • Antipsychotic
  • C-reactive protein
  • E-selectin
  • ICAM-1
  • VCAM-1
  • cardiovascular risk
  • inflammation
  • schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Inflammatory Markers in Schizophrenia : Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. / Meyer, Jonathan M.; McEvoy, Joseph Patrick; Davis, Vicki G.; Goff, Donald C.; Nasrallah, Henry A.; Davis, Sonia M.; Hsiao, John K.; Swartz, Marvin S.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Biological Psychiatry, Vol. 66, No. 11, 01.12.2009, p. 1013-1022.

Research output: Contribution to journalArticle

Meyer, Jonathan M. ; McEvoy, Joseph Patrick ; Davis, Vicki G. ; Goff, Donald C. ; Nasrallah, Henry A. ; Davis, Sonia M. ; Hsiao, John K. ; Swartz, Marvin S. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Inflammatory Markers in Schizophrenia : Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. In: Biological Psychiatry. 2009 ; Vol. 66, No. 11. pp. 1013-1022.
@article{3e4747070adc40fdb9da528a4dd25bb3,
title = "Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study",
abstract = "Background: C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment. Methods: The IM outcomes were compared between antipsychotic treatment groups in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial phase 1 with subjects with laboratory assessments at baseline and 3 months (n = 789). Results: There were significant treatment differences in CRP, E-selectin, and ICAM-1 at 3 months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities as measured by changes in systemic inflammation. C-reactive protein might emerge as a useful target for CV risk outcomes in schizophrenia patients.",
keywords = "Antipsychotic, C-reactive protein, E-selectin, ICAM-1, VCAM-1, cardiovascular risk, inflammation, schizophrenia",
author = "Meyer, {Jonathan M.} and McEvoy, {Joseph Patrick} and Davis, {Vicki G.} and Goff, {Donald C.} and Nasrallah, {Henry A.} and Davis, {Sonia M.} and Hsiao, {John K.} and Swartz, {Marvin S.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.biopsych.2009.06.005",
language = "English (US)",
volume = "66",
pages = "1013--1022",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Inflammatory Markers in Schizophrenia

T2 - Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

AU - Meyer, Jonathan M.

AU - McEvoy, Joseph Patrick

AU - Davis, Vicki G.

AU - Goff, Donald C.

AU - Nasrallah, Henry A.

AU - Davis, Sonia M.

AU - Hsiao, John K.

AU - Swartz, Marvin S.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment. Methods: The IM outcomes were compared between antipsychotic treatment groups in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial phase 1 with subjects with laboratory assessments at baseline and 3 months (n = 789). Results: There were significant treatment differences in CRP, E-selectin, and ICAM-1 at 3 months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities as measured by changes in systemic inflammation. C-reactive protein might emerge as a useful target for CV risk outcomes in schizophrenia patients.

AB - Background: C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment. Methods: The IM outcomes were compared between antipsychotic treatment groups in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial phase 1 with subjects with laboratory assessments at baseline and 3 months (n = 789). Results: There were significant treatment differences in CRP, E-selectin, and ICAM-1 at 3 months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities as measured by changes in systemic inflammation. C-reactive protein might emerge as a useful target for CV risk outcomes in schizophrenia patients.

KW - Antipsychotic

KW - C-reactive protein

KW - E-selectin

KW - ICAM-1

KW - VCAM-1

KW - cardiovascular risk

KW - inflammation

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=70449520471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449520471&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2009.06.005

DO - 10.1016/j.biopsych.2009.06.005

M3 - Article

VL - 66

SP - 1013

EP - 1022

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 11

ER -